190 related articles for article (PubMed ID: 14982308)
1. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma.
Eur J Cancer Care (Engl); 2003 Dec; 12(4):306-7. PubMed ID: 14982308
[No Abstract] [Full Text] [Related]
2. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
[TBL] [Abstract][Full Text] [Related]
3. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.
van Meerten T; Hagenbeek A
Neth J Med; 2009; 67(7):251-9. PubMed ID: 19687518
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
5. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
6. Antibody therapy for non-Hodgkin's lymphoma.
Ansell SM
Curr Opin Mol Ther; 2004 Apr; 6(2):175-81. PubMed ID: 15195930
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
9. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
[TBL] [Abstract][Full Text] [Related]
10. Rituximab (Rituxan/MabThera): the first decade (1993-2003).
Grillo-López AJ
Expert Rev Anticancer Ther; 2003 Dec; 3(6):767-79. PubMed ID: 14686699
[TBL] [Abstract][Full Text] [Related]
11. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
Leonard JP; Coleman M; Ketas JC; Chadburn A; Furman R; Schuster MW; Feldman EJ; Ashe M; Schuster SJ; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Fields SZ; Cesano A; Goldenberg DM
Clin Cancer Res; 2004 Aug; 10(16):5327-34. PubMed ID: 15328168
[TBL] [Abstract][Full Text] [Related]
12. Diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody (rituximab): a case with severe liver dysfunction due to liver cirrhosis and hepatocellular carcinoma.
Nakai S; Masaki T; Shintani T; Deguchi A; Kimura Y; Himoto T; Kurokohchi K; Watanabe S; Kuriyama S
Oncol Rep; 2005 Jun; 13(6):1065-8. PubMed ID: 15870922
[TBL] [Abstract][Full Text] [Related]
13. [Maintenance therapy with rituximab].
Krankenpfl J; 2005; 43(7-10):222-4. PubMed ID: 16515293
[No Abstract] [Full Text] [Related]
14. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma.
Lemieux B; Tartas S; Traulle C; Espinouse D; Thieblemont C; Bouafia F; Alhusein Q; Antal D; Salles G; Coiffier B
Bone Marrow Transplant; 2004 May; 33(9):921-3. PubMed ID: 15034544
[TBL] [Abstract][Full Text] [Related]
15. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
16. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Mey UJ; Orlopp KS; Flieger D; Strehl JW; Ho AD; Hensel M; Bopp C; Gorschlüter M; Wilhelm M; Birkmann J; Kaiser U; Neubauer A; Florschütz A; Rabe C; Hahn C; Glasmacher AG; Schmidt-Wolf IG
Cancer Invest; 2006 Oct; 24(6):593-600. PubMed ID: 16982464
[TBL] [Abstract][Full Text] [Related]
17. Complete molecular remission induced by rituximab in a patient with diffuse large cell lymphoma.
Zinzani PL; Bendandi M; Gamberi B; Magagnoli M; Gherlinzoni F; Tura S
Haematologica; 2000 Apr; 85(4):437-8. PubMed ID: 10756377
[No Abstract] [Full Text] [Related]
18. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma.
Leonard JP; Link BK; Emmanouilides C; Gregory SA; Weisdorf D; Andrey J; Hainsworth J; Sparano JA; Tsai DE; Horning S; Krieg AM; Weiner GJ
Clin Cancer Res; 2007 Oct; 13(20):6168-74. PubMed ID: 17947483
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of rituximab and its clinical use: thought for the best use?
Cartron G; Blasco H; Paintaud G; Watier H; Le Guellec C
Crit Rev Oncol Hematol; 2007 Apr; 62(1):43-52. PubMed ID: 17287129
[TBL] [Abstract][Full Text] [Related]
20. Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice.
Mineo JF; Scheffer A; Karkoutly C; Nouvel L; Kerdraon O; Trauet J; Bordron A; Dessaint JP; Labalette M; Berthou C; Labalette P
Invest Ophthalmol Vis Sci; 2008 Nov; 49(11):4738-45. PubMed ID: 18552383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
